INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 45m ago
HOUSE PTR5m ago
SEC 13F5m ago
ROBINHOOD CHAIN5m ago
Public company

RAREUltragenyx Pharmaceutical Inc.

CIK 0001515673

EDGAR filingsOpen in network
Disclosed transactions3
Buys / sells3 / 0
Max Insider Score24
Connections8with evidence

RARE · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
20
Gilbert Ray Cisneros, Jr.DSelf
RAREUltragenyx Pharmaceutical Inc.
Purchase
BUY$1,001 – $15KSep 29, 2026Oct 12, 2026
traded Sep 29, 2026
+13dHOUSE PTR

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Connected organizationevidence
    ULTRAGENYX PHARMACEUTICAL INC. POLITICAL ACTION COMMITTEE (AKA ULTRAGENYX PAC)FEC Form 1 connected organization: ULTRAGENYX PHARMACEUTICAL INC. (exact legal-name match) · Nov 4, 2026
  • ← Disclosed trade inevidence
    Gilbert Ray Cisneros, Jr.Purchase disclosed 2026-10-12 · Oct 12, 2026
  • ← Lobbied forevidence
    ALPINE GROUP PARTNERS, LLC.
24
Gilbert Ray Cisneros, Jr.DSelf
RAREUltragenyx Pharmaceutical Inc.
Purchase
BUY
$1,001 – $15K
Mar 3, 2026
Apr 7, 2026
traded Mar 3, 2026
+35d
HOUSE PTR

Evidence

24
Gilbert Ray Cisneros, Jr.DSelf
RAREUltragenyx Pharmaceutical Inc.
Purchase
BUY$1,001 – $15KFeb 18, 2026Mar 9, 2026
traded Feb 18, 2026
+19dHOUSE PTR

Evidence

LDA Q2 2026 second quarter · Health issues, Government issues, MED · Aug 26, 2026
  • ← Lobbied forevidence
    MILLER STRATEGIES, LLCLDA RR 2026 first quarter · MED · Aug 26, 2026
  • ← Lobbied forevidence
    FORBES-TATELDA Q1 2026 first quarter · Health issues · Aug 26, 2026
  • ← Lobbied forevidence
    MEHLMAN CONSULTING, INC.LDA Q2 2026 second quarter · Health issues, Budget/appropriations · Aug 26, 2026
  • ← Lobbied forevidence
    AVIVA STRATEGIES (FKA MGB CONSULTING)LDA 1T 2026 first quarter · Health issues · Aug 26, 2026

    • Lobbying

    $830K reported · de-duplicated
    2026 Q2 $390K in-house2026 Q1 $440K in-house
    • MILLER STRATEGIES, LLC$140K2026 Q2 · posted Aug 26, 2026 · MED
    • FORBES-TATE—2026 Q1 · posted Aug 26, 2026 · Health issues
    • MILLER STRATEGIES, LLC—2026 Q1 · posted Aug 26, 2026 · MED
    • ALPINE GROUP PARTNERS, LLC.$60K2026 Q2 · posted Aug 26, 2026 · Health issues, Government issues, MED
    • MEHLMAN CONSULTING, INC.$60K2026 Q2 · posted Aug 26, 2026 · Health issues, Budget/appropriations
    • ALPINE GROUP PARTNERS, LLC.—2026 Q1 · posted Aug 26, 2026 · Health issues, Government issues, MED
    • MILLER STRATEGIES, LLC—2026 Q1 · posted Aug 26, 2026 · MED
    • ALPINE GROUP PARTNERS, LLC.$40K2026 Q1 · posted Aug 26, 2026 · Health issues, Government issues, MED
    • In-house report$390K2026 Q2 · posted Aug 26, 2026 · Health issues, Budget/appropriations, Medicare/Medicaid
    • MEHLMAN CONSULTING, INC.$60K2026 Q1 · posted Aug 26, 2026 · Health issues, Budget/appropriations
    • AVIVA STRATEGIES (FKA MGB CONSULTING)—2026 Q1 · posted Aug 26, 2026 · Health issues
    • In-house report$440K2026 Q1 · posted Aug 26, 2026 · Health issues, Budget/appropriations, Medicare/Medicaid

    Connected PAC contributions

    FEC · direct to members
    • Doris O. MatsuiD$6,500ULTRAGENYX PHARMACEUTICAL INC. POLITICAL ACTION COMMITTEE (AKA ULTRAGENYX PAC)
    • Kevin MullinD$6,500ULTRAGENYX PHARMACEUTICAL INC. POLITICAL ACTION COMMITTEE (AKA ULTRAGENYX PAC)
    • Earl L. "Buddy" CarterR$5,000ULTRAGENYX PHARMACEUTICAL INC. POLITICAL ACTION COMMITTEE (AKA ULTRAGENYX PAC)
    • Diana DeGetteD$5,000ULTRAGENYX PHARMACEUTICAL INC. POLITICAL ACTION COMMITTEE (AKA ULTRAGENYX PAC)
    • Gus M. BilirakisR$2,500
    ULTRAGENYX PHARMACEUTICAL INC. POLITICAL ACTION COMMITTEE (AKA ULTRAGENYX PAC)
  • Lori TrahanD$2,500ULTRAGENYX PHARMACEUTICAL INC. POLITICAL ACTION COMMITTEE (AKA ULTRAGENYX PAC)
  • Bill CassidyR$2,000ULTRAGENYX PHARMACEUTICAL INC. POLITICAL ACTION COMMITTEE (AKA ULTRAGENYX PAC)
  • Josh GottheimerD$1,000ULTRAGENYX PHARMACEUTICAL INC. POLITICAL ACTION COMMITTEE (AKA ULTRAGENYX PAC)
  • Jake AuchinclossD$1,000ULTRAGENYX PHARMACEUTICAL INC. POLITICAL ACTION COMMITTEE (AKA ULTRAGENYX PAC)
  • John JoyceR$1,000ULTRAGENYX PHARMACEUTICAL INC. POLITICAL ACTION COMMITTEE (AKA ULTRAGENYX PAC)